IP Library Granted Patent US 10,570,380
Granted Patent B2
US 10,570,380 · App. 15/113,699 · Granted Feb 25, 2020

Downstream processing of an alkaline phosphatase

Inventors: Luigi Johannes Cornelius Jonk (Utrecht, NL); Stephen Edward Connor (Cambridge, GB); Erik Jan Van Den Berg (Vught, NL); Andrea Van Elsas (Oss, NL); Abhinav Alok Shukla (Morrisville, NC); Heather Bethea Horne (Raleigh, NC); Susan Cook (Flemington, NJ); Timothy Martin Kelly (Raleigh, NC); Victoria Anne Dowling (Boulder, CO); Mialy Fanjamalala Ramaroson (Cary, NC)
Assignee: AM-PHARMA B.V.
C12N9/16A61K38/465A61K47/10A61K47/12A61K47/22A61K47/26C12Y301/03001A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,570,380
App. No.
15/113,699
Granted
Feb 25, 2020
Kind
B2
Abstract

The invention relates to the field of downstream processing (DSP) of an alkaline phosphatase (AP). More specifically, it relates to a method for reducing host cell protein content in a composition comprising AP. The invention further relates to a composition comprising an AP and a reduced content of a host cell protein.

Claims (36)

1. A method for isolating an alkaline phosphatase (AP) comprising:

(a) providing a solid phase comprising a ligand of formula (I):

wherein R is a spacer molecule which links the ligand to the solid phase,

(b) contacting said ligand with a composition comprising an AP that comprises an amino acid sequence 100% identical to SEQ ID NO: 1 and a host cell protein (HCP);

(c) performing two or more wash steps, wherein at least one wash step is performed using a wash buffer comprising between 20-100 mM arginine (Arg), between 0.5-2 M Urea, or between 5-15% ethylene glycol, or any combination thereof; and

(d) eluting said AP from the ligand with an elution buffer;

wherein said eluate comprises less than 100 ppm HCP.

2. A method according to claim 1 , wherein the wash buffer comprises less than 1 mM NaCl.

3. A method according to claim 1 , wherein the elution buffer comprises less than 1 mM NaCl.

4. A method according to claim 1 , wherein the washing buffer comprises about 40 mM Arg.

5. A method according to claim 1 , the method further comprising:

(i) providing a second solid phase comprising a second ligand of formula (II):

(ii) contacting said second ligand with a composition comprising said AP and a HCP, and

(iii) performing two or more wash steps, wherein at least one wash step is performed using a second washing buffer having a pH between 7.5-8.5 and comprising between 0.05-0.2 M NaCl and between 0.1-0.5 M L-Arg.

6. A method according to claim 5 , wherein said second washing buffer comprises between 1-20% glycerol.

7. A method according to claim 5 , wherein (i)-(ii) precedes (a)-(d).

8. A method according to claim 1 , further comprising at least one further purification step selected from the group consisting of anion exchange chromatography, ultrafiltration/diafiltration, viral filtration, and hydrophobic interaction chromatography, and any combination thereof.

9. A method for producing a composition comprising an isolated alkaline phosphatase (AP) comprising an amino acid sequence that is 100% identical to SEQ ID NO: 1, the method comprising

dissolving or diluting said AP in a buffer, which results in a composition having a pH of between 6.5 and 7.5 and comprising between 200-300 mM sorbitol, and/or between 10-40% glycerol, and/or between 5-40 mM histidine, and/or between 10-40 mM citrate, or any combination thereof;

wherein there is no visible particle formation in said composition, using a stability test at 2-8° C. for 2 months.

10. A method according to claim 9 , wherein the composition comprises less than 100 ppm host cell protein (HCP).

11. A composition comprising an isolated alkaline phosphatase obtained from a cell-based expression system, wherein the alkaline phosphatase comprises an amino acid sequence that is 100% identical to SEQ ID NO: 1, wherein the composition comprises less than 100 ppm of a host cell protein (HCP) and wherein the composition does not show visible particle formation during stability testing at 2-8° C. for 2 months.

12. A composition according to claim 11 , wherein the composition has a pH of between 6.5-7.5, and comprises between 10-40 mM citrate or between 5-40 mM histidine.

13. A composition according to claim 12 , wherein the composition comprises between 200-300 mM sorbitol and/or between 10-40% glycerol.

14. A method according to claim 1 , wherein the HCP is a cathepsin-like protein and/or wherein said alkaline phosphatase is obtained from a cell-based expression system.

15. A method for treating a disease or condition that can be improved by the administration of alkaline phosphatase, the method comprising administering to an individual in need thereof a composition according to claim 11 .

16. A method according to claim 10 , wherein the composition comprises AP obtained by a method comprising:

(a) providing a solid phase comprising a ligand of formula (I):

wherein R is a spacer molecule which links the ligand to the solid phase,

(b) contacting said ligand with a composition comprising an AP that comprises an amino acid sequence 100% identical to SEQ ID NO: 1 and a host cell protein (HCP);

(c) performing two or more wash steps, wherein at least one wash step is performed using a wash buffer comprising between 20-100 mM arginine (Arg), between 0.5-2 M Urea, or between 5-15% ethylene glycol, or any combination thereof; and

(d) eluting said AP from the ligand with an elution buffer;

wherein said eluate comprises less than 100 ppm HCP.

17. A composition according to claim 11 , wherein the HCP is a cathepsin-like protein.

18. The composition according to claim 11 , wherein the alkaline phosphatase is recombinant.

19. A composition according to claim 12 , wherein the pH is about 7.

Assignments (5)
RECORDATION OF ADDRESS CHANGE Recorded Jul 2, 2020
From: AM PHARMA B.V.
To: AM PHARMA B.V.
Reel/Frame 053122/0180 →
SECURITY INTEREST Recorded Feb 24, 2020
From: AM-PHARMA B.V.
To: EUROPEAN INVESTMENT BANK
Reel/Frame 052004/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2019
From: JONK, LUIGI JOHANNES CORNELIUS; CONNOR, STEPHEN EDWARD; VAN DEN BERG, ERIK JAN; VAN ELSAS, ANDREA
To: AM-PHARMA B.V.
Reel/Frame 050309/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2019
From: SHUKLA, ABHINAV ALOK; HORNE, HEATHER BETHEA; COOK, SUSAN; KELLY, TIMOTHY MARTIN; DOWLING, VICTORIA ANNE; RAMAROSON, MIALY FANJAMALALA
To: KBI BIOPHARMA, INC.
Reel/Frame 049936/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2019
From: KBI BIOPHARMA, INC.
To: AM-PHARMA B.V.
Reel/Frame 049936/0605 →
Priority Claims (1)
EP 14152542 · Jan 24, 2014 · regional
Continuity (1)
Related Publication 20170009217A1 · Jan 12, 2017
Cited By (4)
US 12,318,434 US 12,472,147 US 12,648,987 US 12,691,077